Drugs that contain Varenicline Tartrate
1. List of Chantix drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6890927 | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May, 2022
(8 months ago) | |
| US7265119 | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Aug, 2022
(6 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6890927
(Pediatric) | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Nov, 2022
(2 months ago) | |
|
US7265119
(Pediatric) | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Feb, 2023
(12 hours from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Feb 22, 2022 |
| Pediatric Exclusivity (PED) | Aug 22, 2022 |
Market Authorisation Date: 10 May, 2006
Treatment: Aid to smoking cessation
Dosage: TABLET;ORAL
How can I launch a generic of CHANTIX before it's patent expiration?
More Information on Dosage
2. List of Tyrvaya drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9504644 | OYSTER POINT PHARMA | Methods of increasing tear production |
Oct, 2035
(12 years from now) | |
| US11224598 | OYSTER POINT PHARMA | Methods of increasing lacrimal proteins |
Oct, 2035
(12 years from now) | |
| US9504645 | OYSTER POINT PHARMA | Pharmaceutical formulations for treating ocular conditions |
Oct, 2035
(12 years from now) | |
| US10456396 | OYSTER POINT PHARMA | Dry eye treatments |
Oct, 2035
(12 years from now) | |
| US9597284 | OYSTER POINT PHARMA | Dry eye treatments |
Oct, 2035
(12 years from now) | |
| US9532944 | OYSTER POINT PHARMA | Methods of improving ocular discomfort |
Oct, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Oct 15, 2024 |
Market Authorisation Date: 15 October, 2021
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION;NASAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic